Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 4Colorectal Neoplasms, Hereditary Nonpolyposis 2Colonic Neoplasms 2Rectal Neoplasms 1HIV Infections 1Disease 1Colonic Polyps 1Colitis, Ulcerative 1Anus Neoplasms 1Adenoma 1

Interventions

Doxorubicin 8Vincristine 7Etoposide 7Cyclophosphamide 7Rituximab 5Prednisone 5Filgrastim 5Zidovudine 3Bleomycin 3Vinblastine 2Thalidomide 2Paclitaxel 2Mitoxantrone 2Interferon-alpha 2Interferon alpha-2 2Dacarbazine 2Cytarabine 2Cisplatin 2ziconotide 1vesnarinone 1tin etiopurpurin 1nirogacestat 1liposomal doxorubicin 1interferon gamma-1b 1fludarabine phosphate 1fludarabine 1efavirenz 1dehydroftorafur 1Whole-Body Irradiation 1Valganciclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × HIV Infections × Colonoscopy × Clear all
NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡